

Date: 8<sup>th</sup> February, 2021

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Tower, Dalal Street,  
Fort, Mumbai – 400 001

Dear Sir / Madam,

**Subject: USFDA inspection at Alembic Pharmaceuticals New Injectable Facility (F-3) at Karkhadi**

We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' New Injectable Facility (F-3) located at Karkhadi from 29<sup>th</sup> January 2021 to 6<sup>th</sup> February 2021. This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with 5 observations.

None of the observations are related to data integrity and are procedural in nature.

The Company is preparing the response to the observations, which will be submitted to USFDA shortly.

The Company is committed to maintain highest quality standards that meet USFDA standards.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**



**Charandeep Singh Saluja**  
Company Secretary

**ALEMBIC PHARMACEUTICALS LIMITED**